The virus is absent in 99.56 percent of Alzheimer's cases
For decades, Alzheimer's disease has resisted simple explanation, but a growing body of evidence now places a familiar and ancient virus — the one responsible for cold sores — closer to the center of the mystery. A large matched study of nearly 350,000 pairs has found that people with a documented herpes simplex virus type 1 infection face roughly 80 percent higher odds of developing Alzheimer's, while those treated with antivirals appear to carry somewhat less risk. The finding does not prove that the virus causes the disease, and experts are careful to note that HSV-1 is extraordinarily common while Alzheimer's, though widespread, is not inevitable — but the question of whether a dormant virus can quietly reshape the aging brain is no longer considered fringe science.
- An 80 percent elevated Alzheimer's risk tied to cold sore virus sounds alarming — but only 0.44 percent of Alzheimer's patients in the study had a recorded HSV-1 diagnosis, meaning the vast majority did not.
- Critics, including one researcher who flagged the study's pharmaceutical funding, warn that spotlighting a virus present in a tiny fraction of cases while absent in 99.56 percent risks distorting public understanding of a complex disease.
- Separate research has shown HSV-1 can enter the brain through the brainstem and nasal cavity, triggering inflammation that lingers even after the virus goes quiet — lending biological plausibility to the statistical association.
- Antiviral treatment was associated with a 17 percent reduction in Alzheimer's risk, and experts are now calling on primary care physicians to take herpes simplex treatment and shingles vaccination more seriously as potential dementia-prevention tools.
- The scientific community's position is cautiously forward-leaning: the correlation is real and worth pursuing, but the causal bridge has not yet been built, and that gap is where the most consequential research still needs to happen.
A study of nearly 350,000 matched pairs has found that people with a documented herpes simplex virus type 1 infection — the virus behind cold sores — were about 80 percent more likely to develop Alzheimer's disease than those without such a diagnosis. Published in BMJ Open and conducted by researchers at Gilead Sciences, the study also found that patients who had taken antiviral medications showed a 17 percent lower likelihood of developing the disease. Associations with increased Alzheimer's risk were found for two related viruses as well: HSV-2 and varicella zoster, which causes chickenpox and shingles.
The scientific community has responded with measured interest rather than alarm. Experts praised the study's scale while pointing out its limits: it relied on health records, meaning the many asymptomatic HSV-1 infections that go undiagnosed were invisible to the analysis. One critic noted that the virus was absent in 99.56 percent of Alzheimer's cases and questioned whether a pharmaceutical company's study could be generalized beyond its specific data source. What the study cannot do, by design, is prove that HSV-1 causes Alzheimer's — only that the two are associated.
The broader scientific conversation, however, has been building for years. Recent research has shown that HSV-1 can enter the brain through the brainstem and olfactory nerve, provoking inflammation that persists even after the virus becomes undetectable. What was once a fringe hypothesis — that viruses might play a meaningful role in neurodegeneration — is increasingly being taken seriously by mainstream neuroscience.
For now, experts recommend that people concerned about cold sores or cognitive health speak with a physician. Vaccines for varicella zoster already exist and may offer protective benefits. The research is advancing, the biological mechanisms are becoming clearer, but the distance between correlation and causation remains the frontier where the real science has yet to arrive.
A new study involving nearly 350,000 matched pairs has found that people diagnosed with Alzheimer's disease were roughly 80 percent more likely to have a history of herpes simplex virus type 1 infection—the virus responsible for cold sores. The finding, published in BMJ Open and conducted by researchers at Gilead Sciences, a pharmaceutical company developing antiviral treatments, has generated headlines suggesting a link between a common infection and one of the most feared neurodegenerative diseases. But the scientific community is urging restraint before anyone starts worrying about their cold sores as a harbinger of cognitive decline.
The study's design was straightforward: researchers identified patients with Alzheimer's disease or Alzheimer's disease-related dementia and matched each one with a control participant of the same age, sex, and geographic location, with similar overall health histories except for the absence of neurological disease. Among the 344,628 pairs examined, 0.44 percent of those with Alzheimer's had a documented HSV-1 diagnosis, compared to 0.25 percent in the control group. After accounting for other health conditions that might influence the outcome, the researchers concluded that an HSV-1 diagnosis was associated with an 80 percent increased risk. They also found that people who had taken antiviral medications to treat HSV-1 showed a 17 percent lower likelihood of developing Alzheimer's. The team extended their analysis to two related viruses—HSV-2, which causes genital herpes, and varicella zoster virus, which causes chickenpox and shingles—and found associations with increased Alzheimer's risk in both cases.
What the study cannot do, however, is prove causation. A case-control study can only demonstrate that two factors are linked; it cannot establish that one causes the other. Several experts have pointed out significant limitations. Dr. Sheona Scales, Director of Research at Alzheimer's Research UK, noted that the study relied solely on health records and administrative claims data, meaning that many HSV-1 infections—which are often asymptomatic—would never have been recorded. Dr. David Vickers of the University of Calgary was more pointed in his criticism, arguing that the research, funded by a pharmaceutical company with commercial interest in antiviral drugs, overstates the importance of HSV-1 by highlighting its presence in a tiny fraction of Alzheimer's cases while ignoring that it is absent in 99.56 percent of them. He also questioned whether the study's data source—drawn from a specific health system—could be generalized to the broader population.
Other researchers, including Professor Tara Spires-Jones of the University of Edinburgh and Professor Cornelia van Duijn of the University of Oxford, praised the study's methodological rigor while emphasizing that the findings represent one piece of a much larger puzzle. Spires-Jones stressed that HSV-1 infection, which is extraordinarily common, is by no means a guarantee of Alzheimer's development. The broader scientific conversation around herpes viruses and neurodegeneration, however, has been building for years. A 2024 study in the Journal of Virology demonstrated that HSV-1 can penetrate the brain through both the brainstem and the olfactory nerve, triggering an inflammatory response that persists even after the virus becomes undetectable. Earlier in 2025, researchers at the University of Illinois Chicago found that HSV-1 particles can be shed in tears and travel through the nasal cavity directly into the brain, potentially contributing to neurological damage. Some researchers have argued that the evidence for a significant role of HSV-1 in Alzheimer's disease is now substantial enough to warrant serious investigation.
Dr. Bryce Vissel, Director of the Centre for Neuroscience and Regenerative Medicine at St Vincent's Hospital Sydney, framed the emerging consensus this way: viruses may not explain everything about Alzheimer's, but they could be central to understanding it. What was once considered a fringe theory, he suggested, is becoming mainstream neuroscience. The question now is not whether to investigate further, but how to act on what is already known. Some experts have pointed out that the new study's finding about antiviral treatment—that it appeared to offer some protection—suggests a practical path forward even while research continues. Professor van Duijn called for greater awareness among primary care physicians and the general public about the potential dementia-related benefits of treating herpes simplex infections and preventing varicella zoster reactivation through vaccination.
For now, the practical advice remains measured. Most people will encounter HSV-1 at some point in their lives, and many will carry the virus without ever developing symptoms. Vaccines exist for varicella zoster virus that can prevent the painful reactivation of the virus as shingles in later life. For HSV-1 and HSV-2, infection often occurs without any noticeable signs. The consensus among experts is that if someone is concerned about a cold sore or their broader health, they should consult a healthcare professional. The research is evolving, the mechanisms are becoming clearer, but the leap from correlation to causation remains unbridged—and that gap is where the real science still needs to happen.
Notable Quotes
HSV-1 infection, which is extremely common in the population, is by no means a guarantee that someone will develop Alzheimer's.— Professor Tara Spires-Jones, University of Edinburgh
Viruses may not explain everything about Alzheimer's, but they could be central to understanding it. This is no longer a fringe theory—it's the next phase of Alzheimer's research.— Dr. Bryce Vissel, Centre for Neuroscience and Regenerative Medicine, St Vincent's Hospital Sydney
The Hearth Conversation Another angle on the story
So this study found that people with Alzheimer's were 80 percent more likely to have had HSV-1. That sounds like a smoking gun.
It sounds that way, but the numbers tell a different story. We're talking about 0.44 percent of Alzheimer's patients versus 0.25 percent in the control group. Both are tiny fractions. The 80 percent increase is real statistically, but it's an increase of something very small.
Why would researchers at a pharmaceutical company studying this so carefully if the effect is that small?
That's a fair question, and some critics have raised it. But the company does develop antivirals, so there's an inherent conflict of interest. That said, the study design itself was rigorous. The real issue is what you can and cannot conclude from this kind of data.
What can't you conclude?
Causation. You can show that two things are linked, but not that one causes the other. Most people with HSV-1 never get Alzheimer's. Most people with Alzheimer's never had a documented HSV-1 infection. The virus is so common that absence of evidence isn't evidence of absence.
But there is other research suggesting the virus can damage the brain?
Yes. Studies show HSV-1 can enter the brain and trigger inflammation. It can travel through the olfactory nerve. The inflammation can persist even after the virus is gone. That's the interesting part—not this one study, but the accumulating picture.
So what should someone actually do if they get cold sores?
Treat them if they're bothersome. If you're concerned, talk to a doctor. But getting a cold sore doesn't mean you're on a path to dementia. The virus is in most of us. The question researchers are asking now is whether treating it more aggressively might offer some protection—and that's still being studied.